Fàtima Sabench1,2, Laia Bertran2, Margarita Vives1, Marta París1, Carmen Aguilar2, Salomé Martínez2, Jessica Binetti2,3, Monica Real3, Alja Alibalic3, Cristóbal Richart2, Daniel Del Castillo1,2, Teresa Auguet4,5. 1. Servei de Cirurgia, Departament de Medicina I Cirurgia, Hospital Sant Joan de Reus, Universitat Rovira I Virgili (URV), Institut d'Investigació Sanitària Pere Virgili (IISPV), Avinguda Doctor Josep Laporte, 2, 43204, Reus, Spain. 2. Grup de Recerca GEMMAIR (AGAUR) - Medicina Aplicada, Departament de Medicina I Cirurgia, URV, IISPV, Mallafré Guasch, 4, 43007, Tarragona, Spain. 3. Servei Medicina Interna, Hospital Universitari Joan XXIII Tarragona, Mallafré Guasch, 4, 43007, Tarragona, Spain. 4. Grup de Recerca GEMMAIR (AGAUR) - Medicina Aplicada, Departament de Medicina I Cirurgia, URV, IISPV, Mallafré Guasch, 4, 43007, Tarragona, Spain. tauguet.hj23.ics@gencat.cat. 5. Servei Medicina Interna, Hospital Universitari Joan XXIII Tarragona, Mallafré Guasch, 4, 43007, Tarragona, Spain. tauguet.hj23.ics@gencat.cat.
Abstract
PURPOSE: Given that obesity is a major medical problem associated with non-alcoholic fatty liver disease and the lack of studies on postsurgery weight loss according to hepatic histology, we aimed to analyse weight loss indicators according to non-alcoholic steatohepatitis (NASH) presence one and 2 years postsurgery. MATERIALS AND METHODS: The weight loss pattern of 410 women with severe obesity (SO) was analysed after sleeve gastrectomy (SG, n = 191) and Roux-en-Y gastric bypass (RYGB, n = 219) according to NASH presence at baseline and at 12 and 24 months postsurgery. Weight loss indicators: expected BMI (eBMI), excess BMI loss percentage (%EBMIL), total weight loss percentage (%TWL) and alterable weight loss percentage (%AWL). RESULTS: Unlike RYGB, after SG, a higher percentage of NASH patients do not reach the eBMI 2 years postsurgery. %TWL and %AWL presented no differences after RYGB despite the presence of NASH. After SG, there is a worse ponderal evolution of all indicators analysed in the presence of NASH. Unlike SG, diabetic patients lose less weight than non-diabetic patients after RYGB. The presence of NASH in diabetics had no impact on weight loss indicators, but in non-diabetics, it had an impact, particularly in the SG group. CONCLUSION: The presence of NASH suggests a worse weight loss pattern through all the analysed indicators one and 2 years after SG in women. The presence of T2DM appears to result in less weight loss after RYGB, but only non-diabetic women presenting NASH lose less weight that non-diabetic women in the absence of NASH after SG.
PURPOSE: Given that obesity is a major medical problem associated with non-alcoholic fatty liver disease and the lack of studies on postsurgery weight loss according to hepatic histology, we aimed to analyse weight loss indicators according to non-alcoholic steatohepatitis (NASH) presence one and 2 years postsurgery. MATERIALS AND METHODS: The weight loss pattern of 410 women with severe obesity (SO) was analysed after sleeve gastrectomy (SG, n = 191) and Roux-en-Y gastric bypass (RYGB, n = 219) according to NASH presence at baseline and at 12 and 24 months postsurgery. Weight loss indicators: expected BMI (eBMI), excess BMI loss percentage (%EBMIL), total weight loss percentage (%TWL) and alterable weight loss percentage (%AWL). RESULTS: Unlike RYGB, after SG, a higher percentage of NASH patients do not reach the eBMI 2 years postsurgery. %TWL and %AWL presented no differences after RYGB despite the presence of NASH. After SG, there is a worse ponderal evolution of all indicators analysed in the presence of NASH. Unlike SG, diabetic patients lose less weight than non-diabetic patients after RYGB. The presence of NASH in diabetics had no impact on weight loss indicators, but in non-diabetics, it had an impact, particularly in the SG group. CONCLUSION: The presence of NASH suggests a worse weight loss pattern through all the analysed indicators one and 2 years after SG in women. The presence of T2DM appears to result in less weight loss after RYGB, but only non-diabetic women presenting NASH lose less weight that non-diabetic women in the absence of NASH after SG.
Authors: Marc Beisani; Fàtima Sabench Pereferrer; Ramón Vilallonga; Óscar González López; Alicia Molina López; Daniel Del Castillo Dejardin; Amador García Ruiz de Gordejuela; José Manuel Fort López-Barajas; Manel Armengol Carrasco Journal: Obes Surg Date: 2021-01-04 Impact factor: 4.129
Authors: Guilherme M Campos; Charlotte Rabl; Kathleen Mulligan; Andrew Posselt; Stanley J Rogers; Antonio C Westphalen; Feng Lin; Eric Vittinghoff Journal: Arch Surg Date: 2008-09
Authors: M Garciacaballero; A Reyes-Ortiz; M García; J M Martínez-Moreno; J A Toval; A García; A Mínguez; D Osorio; J M Mata; F Miralles Journal: Obes Surg Date: 2014-12 Impact factor: 4.129
Authors: Ziad Abbassi; Lorenzo Orci; Jeremy Meyer; Sebastian Douglas Sgardello; Nicolas Goossens; Laura Rubbia-Brandt; Laurent Spahr; Nicolas Christian Buchs; Stefan Paul Mönig; Christian Toso; Monika Elisabeth Hagen; Minoa Karin Jung Journal: Obes Surg Date: 2021-09-21 Impact factor: 4.129
Authors: Jadine Scragg; Leah Avery; Sophie Cassidy; Guy Taylor; Laura Haigh; Marie Boyle; Michael I Trenell; Quentin M Anstee; Stuart McPherson; Kate Hallsworth Journal: Clin Transl Gastroenterol Date: 2020-09 Impact factor: 4.488